BioMerieux Other Share Holders Equity 2017-2023 | BMXMF
BioMerieux other share holders equity from 2017 to 2023. Other share holders equity can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- BioMerieux other share holders equity for the quarter ending December 31, 2023 was $0.000B, a 100% decline year-over-year.
- BioMerieux other share holders equity for 2023 was $0B, a NAN% decline from 2022.
- BioMerieux other share holders equity for 2022 was $0B, a NAN% decline from 2021.
- BioMerieux other share holders equity for 2021 was $0B, a NAN% decline from 2020.
| BioMerieux Annual Other Share Holders Equity (Millions of US $) |
|
|---|---|
| 2023 | $ |
| 2022 | $ |
| 2021 | $ |
| 2020 | $ |
| 2019 | $ |
| 2018 | $ |
| 2017 | $ |
| 2016 | $ |
| 2015 | $ |
| BioMerieux Quarterly Other Share Holders Equity (Millions of US $) |
|
|---|---|
| 2023-12-31 | $0 |
| 2022-12-31 | $41 |
| 2022-06-30 | $48 |
| 2021-12-31 | $61 |
| 2021-06-30 | $61 |
| 2020-12-31 | $57 |
| 2019-12-31 | $57 |
| 2019-06-30 | $58 |
| 2018-12-31 | $87 |
| 2018-06-30 | |
| 2017-12-31 | $-1 |
| 2017-06-30 | $2 |
| 2016-12-31 | $2 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $12.119B | $3.977B |
| bioM?rieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioM?rieux S.A. is based in Marcy L Etoile, France. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $93.604B | 11.61 |
| Cencora (COR) | United States | $48.412B | 17.85 |
| DiDi Global (DIDIY) | China | $22.941B | 0.00 |
| Natera (NTRA) | United States | $22.359B | 0.00 |
| ICON (ICLR) | Ireland | $17.552B | 15.63 |
| Viatris (VTRS) | United States | $15.815B | 4.87 |
| Avantor (AVTR) | United States | $13.857B | 20.78 |
| Revvity (RVTY) | United States | $13.522B | 23.49 |
| CochLear (CHEOY) | Australia | $12.586B | 0.00 |
| Solventum (SOLV) | United States | $12.029B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.624B | 29.93 |
| Charles River Laboratories (CRL) | United States | $9.930B | 19.19 |
| HealthEquity (HQY) | United States | $9.139B | 49.60 |
| Doximity (DOCS) | United States | $8.961B | 52.75 |
| Sonic Healthcare (SKHHY) | Australia | $8.813B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.977B | 32.47 |
| Life Times (LTH) | United States | $5.046B | 33.40 |
| Organon (OGN) | United States | $3.835B | 3.87 |
| Sotera Health (SHC) | United States | $3.515B | 18.80 |
| BrightSpring Health Services (BTSG) | United States | $3.265B | 69.44 |
| Surgery Partners (SGRY) | United States | $2.968B | 33.84 |
| Concentras Parent (CON) | United States | $2.735B | 0.00 |
| PACS (PACS) | United States | $2.522B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.320B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.255B | 0.00 |
| Premier (PINC) | United States | $2.155B | 11.21 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.995B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.980B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.791B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.635B | 42.90 |
| Progyny (PGNY) | United States | $1.275B | 25.81 |
| Pediatrix Medical (MD) | United States | $1.267B | 12.40 |
| CareDx (CDNA) | United States | $1.211B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.193B | 0.00 | |
| AMN Healthcare Services Inc (AMN) | United States | $0.978B | 6.62 |
| Embecta (EMBC) | United States | $0.808B | 5.38 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
| Agilon Health (AGL) | United States | $0.733B | 0.00 |
| SBC Medicals (SBC) | United States | $0.670B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.627B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.526B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.467B | 0.00 |
| DocGo (DCGO) | United States | $0.420B | 15.85 |
| Enhabit (EHAB) | United States | $0.376B | 32.48 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.304B | 0.00 |
| ModivCare (MODV) | United States | $0.250B | 13.54 |
| LifeMD (LFMD) | United States | $0.246B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.206B | 0.00 |
| Biodesix (BDSX) | United States | $0.175B | 0.00 |
| Nutex Health (NUTX) | United States | $0.173B | 0.00 |
| Beauty Health (SKIN) | United States | $0.173B | 0.00 |
| MultiPlan (MPLN) | United States | $0.114B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.094B | 0.00 |
| So-Young (SY) | China | $0.093B | 17.98 |
| Singular Genomics Systems (OMIC) | United States | $0.055B | 0.00 |
| OncoCyte (OCX) | United States | $0.045B | 0.00 |
| NeueHealth (NEUE) | United States | $0.042B | 1.11 |
| Co-Diagnostics (CODX) | United States | $0.034B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.031B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.027B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.022B | 0.00 |
| Oncology Institute (TOI) | United States | $0.012B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.010B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.007B | 0.00 |
| KindlyMD (KDLY) | United States | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |